Victory Capital Management
CLRB icon

Victory Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Victory Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10
Closed -$4K – 2662
2020
Q1 		$4K Buy
+10
New +$6.69K ﹤0.01% 3515
2019
Q4 		– Sell
-4
Closed -$3K – 2761
2019
Q3 		$3K Buy
+4
New +$2.61K ﹤0.01% 3548

Other funds holding CLRB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Victory Capital Management's CLRB Position: Q2 2020 in Review

Victory Capital Management sold out of Cellectar Biosciences (CLRB) in Q2 2020, closing a stake of 10 shares — an estimated $4K sold.

Victory Capital Management first reported a position in CLRB in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2020. 23 funds tracked by Wall St. Rank hold CLRB as of Q2 2020.

  • Victory Capital Management reported no remaining Cellectar Biosciences position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 10 Cellectar Biosciences shares in Q2 2020, an estimated $4K.
  • Victory Capital Management first reported a position in Cellectar Biosciences in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Cellectar Biosciences position peaked at $4K in Q1 2020.
  • 23 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.